Devon Energy Corp vs Viatris Inc — how do they compare? Devon Energy Corp trades at $44.97 (market cap $49.94B), while Viatris Inc trades at $16.26 (market cap $18.69B). The key difference: Devon Energy Corp is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| DVN | VTRS | |
|---|---|---|
Market Cap | $49.94B | $18.69B |
Sector | Energy | Health |
52-Week High | $52.07 | $17.86 |
52-Week Low | $31.74 | $9.49 |
Enterprise Value | $60.68B | $30.80B |
Dividend Yield | 2.82% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $45.36, up 5.54% with strong technical momentum and bullish analyst sentiment. The company delivered robust Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising dividends 33% and accelerating debt reduction. Valuation remains attractive with P/E of 9.87 and EV/EBITDA of 6.89, supported by $1.7B Q2 free cash flow and $8B buyback authorization.
Outlook remains positive with merger synergies tracking ahead of schedule and 2026 revenue guidance of $19.7B. Key risks include oil price volatility and integration execution from the Coterra merger. With 71% analyst buy ratings and $61.91 consensus target representing 36% upside, DVN offers compelling value for energy investors seeking growth and shareholder returns.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Trailing returns across standard periods
Latest headlines on both assets
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →